|
| |
Viventia Biotech IncViventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phase II/III global study with Proxinium™ for the treatment of head and neck cancer. Viventia's second product candidate, Vicinium™ for the treatment of bladder cancer, is in an ongoing Phase I/II clinical trial. In addition, Viventia has several other product candidates in pre-clinical development.
Our platform of technologies is based upon the isolation of human monoclonal antibodies obtained from cancer patients, and the development of those antibodies as Armed Antibodies™ to deliver cytotoxic (cancer killing) ‘‘payloads’’ to cancer cells. We believe that this approach has the potential to be safer and more beneficial than existing cancer drugs.
Viventia is building fully integrated capabilities spanning all phases of the drug development cycle, from drug discovery, screening and pre-clinical development through to clinical trials, production and commercial manufacturing.
Recent Publications by Viventia Biotech Inc: |  |
A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.
VB4-845 is a scFv-Pseudomonas exotoxin A fusion construct that targets... | 19th November, 2009
| Viventia Biotech Inc., Winnipeg, Manitoba, Canada.
| Drug Des Devel Ther. 2009 Feb 6;2:105-114.
|
A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.
VB4-845 is a novel recombinant fusion protein that targets the epithelial... | 19th November, 2008
| Viventia Biotech Inc., 147 Hamelin St., Winnipeg, MB, Canada R3T 3Z1.
| Med Oncol. 2009;26(3):257-64. Epub 2008 Oct 28.
DOI Direct Link |
A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab PF-2D in tandem with mass spectrometry.
Mapping differential expression of soluble proteins has become fairly... | 25th October, 2006
| Viventia Biotech Inc., 147 Hamelin street, Winnipeg, MB, Canada R3T3Z1.
| Biochem Biophys Res Commun. 2006 Sep 29;348(3):1055-62. Epub 2006 Aug 7.
DOI Direct Link |
Effective tumor targeting: strategies for the delivery of Armed Antibodies.
It has long been realized that the presence of tumor-associated antigens... | 14th June, 2005
| Viventia Biotech Inc, 147 Hamelin Street, Winnipeg, Manitoba R3T 3Z1,
| Curr Opin Drug Discov Devel. 2005 Mar;8(2):177-83.
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 467 times since April 2007, the link to the organisation's website has been followed 59 times Recent Search Terms used to find this page: Viventia Biotech Inc. 147 Hamelin Street | Viventia Winnipeg address fax | viventia biotech 2009 | viventia biotech | viventia biotech inc 2009 | viventia biotech | viventia biotech | viventia | VIVENTIA BIO | VIVENTIA BIO | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Viventia Biotech Inc |
